Nutritional screening and early treatment of malnutrition in cancer patients

Journal of Cachexia, Sarcopenia and Muscle

Volumn 2, Issue 1, 2011, Pages 27-35

  Santarpia, Lidia ^a   Contaldo, Franco ^a   Pasanisi, Fabrizio ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cancer; Malnutrition; Nutritional screening

Indexed keywords

ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; CHOLESTEROL; CHOLINESTERASE; CISPLATIN; DEXAMETHASONE; ETOPOSIDE; IRINOTECAN; METHYLPREDNISOLONE; PACLITAXEL; PREALBUMIN; PREDNISOLONE; SERUM ALBUMIN;

ABDOMINAL PAIN; ALBUMIN BLOOD LEVEL; CACHEXIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CHOLESTEROL BLOOD LEVEL; DIARRHEA; DISTRESS SYNDROME; DNA DAMAGE; EARLY INTERVENTION; FOLLOW UP; HUMAN; MALNUTRITION; MEDICAL HISTORY; MOUTH HYGIENE; NAUSEA; NUTRITIONAL ASSESSMENT; NUTRITIONAL PARAMETERS; ORAL MUCOSITIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN METABOLISM; QUALITY OF LIFE; REVIEW; VOMITING;

EID: 84858112321     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1007/s13539-011-0022-x     Document Type: Review

References (66)

1. van Bokhorst-de van der Schueren MA. Nutritional support strategies for malnourished cancer patients. Eur J Oncol Nurs. 2005; 9(Suppl 2): S74-83.
2. Fearon KC, Voss AC, Hustead DS, Cancer Cachexia Study Group. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr. 2006; 83: 1345-50.
3. von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle. 2010; 1: 159-67.
4. Capra S, Ferguson M, Ried K. Cancer: impact of nutrition intervention outcome-nutrition issues for patients. Nutrition. 2001; 17: 769-72.
5. Norman K, Pichard C, Lochs H, Pirlich M. Prognostic impact of disease-related malnutrition. Clin Nutr. 2008; 27: 5-15.
6. Alexandre J, Gross-Goupil M, Falssard B, et al. Evaluation of the nutritional and inflammatory status in cancer patients for the risk assesment of severe haematological toxicity following chemotherapy. Ann Oncol. 2003; 14: 36-41.
7. Andreyev HJ et al. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer. 1998; 34: 503-9.
8. Khalid U, Spiro A, Baldwin C, Sharma B, McGough C, Norman AR, et al. Symptoms and weight loss in patients with gastrointestinal and lung cancer at presentation. Support Care Cancer. 2007; 15: 39-46.
9. Gupta D, Lis CG, Vashi PG, Lammersfeld CA. Impact of improved nutritional status on survival in ovarian cancer. Support Care Cancer. 2010; 18: 373-81.
10. Skipworth RJE, Stewart GD, Dejong CHC, Preston T, Fearon KC. Pathophysiology of cancer cachexia: much more than host-tumor interaction? Clin Nutr. 2007; 26: 667-76.
11. Marín Caro MM, Laviano A, Pichard C. Nutritional intervention and quality of life in adult oncology patients. Clin Nutr. 2007; 26: 289-301.
12. Santarpia L, Alfonsi L, Pasanisi F, De Caprio C, Scalfi L, Contaldo F. Predictive factors of survival in patients with peritoneal carcinomatosis on home parenteral nutrition. Nutrition. 2006; 22: 355-60.
13. Gaidos JK, Gaidos JK, Draganov PV. Treatment of malignant gastric outlet obstruction with endoscopically placed self-expandable metal stents. World J Gastroenterol 2009; 21; 15: 4365-71.
14. Alexandre J, Gross-Goupil M, Falissard B, Nguyen ML, Gornet JM, Misset JL, et al. Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy. Ann Oncol. 2003; 14: 36-41.
15. Murry D, Riva L, Poplack D. Impact of nutrition on pharmacokinetics of antineoplastic agents. Int J Cancer. 1998; S11: 48-51.
16. Campbell KL, Ash S, Davies PS, Bauer JD. Randomized controlled trial of nutritional counseling on body composition and dietary intake in severe CKD. Am J Kidney Dis. 2008; 51: 748-58.
17. Das P, Cantor SB, Parker CL, Zampieri JB, Baschnagel A, Eng C, et al. Long-term quality of life after radiotherapy for the treatment of anal cancer. Cancer. 2010; 116: 822-9.
18. Ozturk A, Sarihan S, Ercan I, Karadag M. Evaluating quality of life and pulmonary function of long-term survivors of non-small cell lung cancer treated with radical or postoperative radiotherapy. Am J Clin Oncol. 2009; 32: 65-72.
19. Vilmar A, Santoni-Rugiu E, Sørensen JB. ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial. Eur J Cancer. 2010; 46: 1554-62.
20. Muscaritoli M, Anker SD, Argilés J, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". Clin Nutr. 2010; 29: 154-9.
21. Lochs H, Allison SP, Meier R, et al. Introductory to the ESPEN guidelines on enteral nutrition: terminology, definitions and general topics. Clin Nutr. 2006; 25: 180-6.
22. Braun TP, Marks DL. Pathophysiology and treatment of inflammatory anorexia in chronic disease. J Cachexia Sarcopenia Muscle. 2010; 1: 135-45.
23. Saini A, Al-Shanti N, Stewart CE. Waste management-cytokines, growth factors and cachexia. Cytokine Growth Factor Rev. 2006; 17: 475-86.
24. Costelli P, Baccino FM. Mechanisms of skeletal muscle depletion in wasting syndromes: role of ATP-ubiquitin-dependent proteolysis. Curr Opin Clin Nutr Metab Care. 2003; 6: 407-12.
25. Tisdale MJ. The "cancer cachectic factors". Support Care Cancer. 2003; 11: 73-8.
26. Nourissat A, Vasson MP, Merrouche Y, Bouteloup C, Goutte M, Mille D, et al. Relationship between nutritional status and quality of life in patients with cancer. Eur J Cancer. 2008; 44: 1238-42.
27. Huhmann MB, Cunningham RS. Importance of nutritional screening in treatment of cancer-related weight loss. Lancet Oncol. 2005; 6: 334-43.
28. Barbosa-Silva MC. Subjective and objective nutritional assessment methods: what do they really assess? Curr Opin Clin Nutr Metab Care. 2008; 11: 248-54.
29. Batel-Copel LM, Kornblith AB, Batel PC, Holland JC. Do oncologists have an increasing interest in the quality of life of their patients? A literature review of the last 15 years. Eur J Cancer. 1997; 33: 29-32.
30. Kondrup J, Allison SP, Elia M, Vellas B, Plauth M. Educational and Clinical Practice Committee, European Society of Parenteral and Enteral Nutrition (ESPEN). ESPEN guidelines for nutrition screening 2002. Clin Nutr. 2003; 22: 415-21.
31. Duguet A et al. Summary report of the standards, options and recommendations for malnutrition and nutritional assessment in patients with cancer 1999. Br J Cancer 2003; 89(Suppl. 1): S92-S97.
32. Isenring E, Bauer J, Capra S. The scored Patient-generated Subjective Global Assessment (PG-SGA) and its association with quality of life in ambulatory patients receiving radiotherapy. Eur J Clin Nutr. 2003; 57: 305-9.
33. Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME. Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol. 2005; 23: 1431-8.
34. Bozzetti F, Arends J, Lundholm K, Micklewright A, Zurcher G, Muscaritoli M, et al. ESPEN guidelines on parenteral nutrition: non-surgical oncology. Clin Nutr. 2009; 28: 445-54.
35. Santarpia L, Marra M, Montagnese C, Alfonsi L, Pasanisi F, Contaldo F. Prognostic significance of bioelectrical impedance phase angle in advanced cancer: preliminary observations. Nutrition. 2009; 25: 930-1.
36. Fuhrman MP, Charney P, Mueller CM. Hepatic proteins and nutrition assessment. J Am Diet Assoc. 2004; 104: 1258-64.
37. Gu S-Z et al. Alterations of serum cholinesterase in patients with gastric cancer. World J Gastrenterol. 2005; 11: 4604-6.
38. Grandone L, Santarpia L, Alfonsi L, Pagano MC, Pasanisi F, Contaldo F. Serum cholinesterase as indicator of parenteral nutrition efficacy in protein energy malnutrition: four case reports. e-SPEN (The European e-Journal of Clinical Nutrition and Metabolism) - 18 November 2009 (10. 1016/j. eclnm. 2009. 10. 006).
39. Bozzetti F. Effects of artificial nutrition on the nutritional status of cancer patients. J Parenter Enteral Nutr. 1989; 13: 406-20.
40. Mekhail TM, Adelstein DJ, Rybicki LA, Larto MA, Saxton JP, Lavertu P. Enteral Nutrition during the treatment of head and neck carcinoma is a percutaneous endoscopic gastrostomy tube preferable to a nasogastric tube? Cancer. 2001; 91: 1785-90.
41. Cady J. Nutritional support during radiotherapy for head and neck cancer: the role of prophylactic feeding tube placement. Clin J Oncol Nurs. 2007; 11: 875-80.
42. Gunnlaugsson A, Kjellén E, Nilsson P, Bendahl PO, Willner J, Johnsson A. Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiotherapy in locally advanced rectal cancer. Acta Oncol. 2007; 46: 937-44.
43. Gore JI, Surawicz C. Severe acute diarrhea. Gastroenterol Clin North Am. 2003; 32: 1249-67.
44. MacNaughton WK. Review article: new insights into the pathogenesis of radiation-induced intestinal dysfunction. Aliment Pharmacol Ther. 2000; 14: 523-8.
45. Fearon KC et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomized double blind trial. Gut. 2003; 52: 1479-86.
46. Linard C, Ropenga A, Vozenin-Brotons MC, Chapel A, Mathe D. Abdominal irradiation increases inflammatory cytokine expression and activates NF-kappaB in rat ileal muscularis layer. Am J Physiol Gastrointest Liver Physiol. 2003; 285: G556-65.
47. Cerchietti LC, Navigante AH, Castro MA. Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutr Cancer. 2007; 59: 14-20.
48. Dewey A, Baughan C, Dean T, Higgins B, Johnson I. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev. 2007; 24: CD004597.
49. Siddiqui R, Pandya D, Harvey K, Zaloga GP. Nutrition modulation of cachexia/proteolysis. Nutr Clin Pract. 2006; 21: 155-67.
50. Heuberger W, Berardi S, Jacky E, et al. Increased urinary excretion of carnitine in patients treated with cisplatin. Eur J Clin Pharmacol. 1998; 54: 503-8.
51. Federico A, Iodice P, Federico P, et al. Effects of selenium and zinc supplementation on nutritional status in patients with cancer of digestive tract. Eur J Clin Nutr. 2001; 55: 293-7.
52. Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesiemia. J Natl Cancer Inst. 2005; 97: 1221-4.
53. Maltoni M, Nanni O, Scarpi E, Rossi D, Serra P, Amadori D. High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials. Ann Oncol. 2001; 12: 289-300.
54. Wood L, Palmer M, Hewitt J, Urtasun R, Bruera E, Rapp E, et al. Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein -mediated drug resistance in the first-line management of small-cell lung carcinoma. Br J Cancer. 1998; 77: 627-31.
55. Morley JE. Orexigenic and anabolic agents. Clin Geriatr Med. 2002; 18: 853-66.
56. Jatoi A. Weight loss in patients with advanced cancer: effects, causes, and potential management. Curr Opin Support Palliat Care. 2008; 2: 45-8.
57. Quinn B, Potting CM, Stone R, Blijlevens NM, Fliedner M, Margulies A, et al. Guidelines for the assessment of oral mucositis in adult chemotherapy, radiotherapy and haematopoietic stem cell transplant patients. Eur J Cancer. 2008; 44: 61-72.
58. Akamizu T, Kangawa K. Ghrelin for cachexia. J Cachexia Sarcopenia Muscle. 2010; 1: 169-76.
59. Worthington HV, Clarkson JE, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2007; 17: CD000978.
60. Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007; 109: 820-31.
61. Contaldo F, Alfonsi L, Santarpia L, Pasanisi F. Artificial nutrition at the bioethic cross-road between treatment and basic health care. Clin Nutr. 2006; 25: 171-2.
62. Bozzetti F. Home total parenteral nutrition in incurable cancer patients: a therapy, a basic humane care or something in between? Clin Nutr. 2003; 22: 109-11.
63. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008; 27: 793-9.
64. Bozzetti F. The patient with incurable aphagic cancer: to feed or not to feed? Nutrition. 2001; 17: 676-7.
65. Violante G, Alfonsi L, Santarpia L, Cillis MC, Negro G, De Caprio C, et al. Adult home parenteral nutrition: a clinical evaluation after a 3-year experience in a Southern European centre. Eur J Clin Nutr. 2006; 60: 58-61.
66. von Haehling S, Morley JE, Coats AJ, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle. 2010; 1: 7-8.